Company Description
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications.
Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis.
The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions.
It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance’s botulinum toxin type A.
Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2014 |
| IPO Date | Aug 13, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Gerald Proehl |
Contact Details
Address: 3525 Del Mar Heights Rd., Suite 332 San Diego, California 92130 United States | |
| Phone | 858 800 2543 |
| Website | dermatarx.com |
Stock Details
| Ticker Symbol | DRMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 0001853816 |
| CUSIP Number | 249845108 |
| ISIN Number | US2498453065 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gerald T. Proehl | Founder, President, Chief Executive Officer and Chairman |
| David F. Hale | Co-Founder and Lead Independent Director |
| Kyri K. Van Hoose CPA, M.B.A. | Senior Vice President and Chief Financial Officer |
| Dr. Christopher J. Nardo M.P.H., Ph.D. | Senior Vice President and Chief Development Officer |
| Sean Proehl | Associate General Counsel |
| Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. | Senior Vice President of Regulatory Affairs and Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | EFFECT | Notice of Effectiveness |
| Apr 23, 2025 | 424B3 | Prospectus |
| Apr 15, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 15, 2025 | 8-K | Current Report |
| Apr 7, 2025 | SCHEDULE 13D/A | Filing |
| Apr 3, 2025 | SCHEDULE 13D/A | Filing |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 8-K | Current Report |